TMCnet News
Research and Markets: PharmaPoint: Neuropathic Pain - Global Drug Forecast and Market Analysis to 2022DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/djkdls/pharmapoint) has announced the addition of the "PharmaPoint: Neuropathic Pain - Global Drug Forecast and Market Analysis to 2022" report to their offering. Novel Therapies to Revitalize the Neuropathic Pain Treatment Market Landscape by 2022 This report provides an overview of three neuropathic pain indications - painful diabetic neuropathy, postherpetic neuralgia and trigeminal neuralgia - including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. It also gives annualized neuropathic pain therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 to 2022. With seven promising neuropathic pain (NP) treatments expected to be launched in the coming years, the NP therapeutics market value - covering painful diabetic neuropathy, postherpetic neuralgia and trigeminal neuralgia - is forecast to increase from $2.58 billion in 2012 t $3.53 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 3.19%, says research and consulting firm The authors. According to the company's latest report*, seven novel pipeline drugs targeting these three indications will enter the market before 2022. These include Daiichi Sankyo's DS-5565, Convergence's (News - Alert) CNV-2197944, Grünenthal's Cebranopadol and Impax's Eladur. The authors expects the sales of these pipeline therapies to account for 23.8% of the global NP market by 2022. Sally Chege, Ph.D., The authors's Analyst covering Neurology, says: Although many of the available drugs offer some degree of efficacy in terms of pain relief, there still remains vast room for improvement in efficacy, safety, drug delivery, and dosing convenience. Furthermore, all three market-leading therapies, Pfizer's Lyrica, Eli Lilly's Cymbalta and Endo Health's Lidoderm, will lose patent protection over the forecast period, therefore increasing the risk of generic erosion. The authors believes that there are opportunities for companies to enter the NP market through the development of novel drugs, provided that their product offerings target some of these unmet needs. However, as Chege continues: Steep research and development costs, as well as the high failure rate of pain medications in NP clinical trials, have led many larger pharmaceutical companies to deprioritize the development of new NP therapies. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Unmet Need and Opportunity 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned
For more information visit http://www.researchandmarkets.com/research/djkdls/pharmapoint
|
